Wayne Paterson

Chief Executive Officer

Wayne Paterson has held numerous, senior positions in multi-national pharmaceutical
companies and has lived in seven countries during the past 25 years. Throughout his
career, he has been responsible for building and managing businesses throughout the
world, including mergers/integrations/acquisitions and major restructures as President
and CEO.
From 2005 to 2013, he held senior positions at Merck Kgaa. In his most recent role as
President of Europe, Canada and Australia, he managed over $3 billion in sales with an
operational budget of $500 million and was a member of the Global Executive Board.
Paterson also held the position of Global Director (Executive Vice President) of Cardio
Metabolic Care and General Medicine, with revenue responsibility of $1.5 billion, and was
responsible for all aspects of company strategy, including manufacturing strategies,
commercial operations and budgets. Between 2010 and 2012, he was President and CEO
of Emerging Markets including Russia, China, India and Brazil (as well as 40 other
countries), and was a member of the Executive Board. As President of Merck’s Japanese
operations between 2007 and 2010 in Tokyo, he grew the business at a CAGR of 93%
against the market growth of 3%.
Between 1994 and 2005, Paterson served at Roche Pharmaceuticals. In 1998, he was
Marketing Director in Shanghai, China, where he launched eight Roche/Genentech
Oncology biotech products as well as some major cardiovascular drugs. He went to
become Head of Pharmaceuticals in Roche’s South Korean operation between 2001-
Paterson was also a Non-Executive Director of Cepheid (NASDAQ:CHPD), a molecular
diagnostics company based in California until its recent sale.
Paterson is an Australian national and has resided overseas since 1998, having lived in
China, Singapore, Korea, Japan, Switzerland and the US. He now lives in Minneapolis.
Paterson holds an MBA from the University of Southern Queensland, and business
studies from the Queensland University of Technology. He has also studied business
courses at Northwestern University (Kellogg School of Management) in Chicago, IMD
Business School in Switzerland, INSEAD in France and Hong Kong University of

John Seaberg


From 2007 until May 2014, John Seaberg was Founder, Chairman and CEO of NeoChord Inc., a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques.
Previously, he was with Guidant Corp. from 1996 until 2006 (subsequently acquired by Boston Scientific Corp.). During his tenure at Guidant, Seaberg served in various executive-level positions in sales and marketing, including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery, and Vice President of Sales for Cardiac Rhythm Management, where he managed a field sales team of more than 600 people and over $1 billion in revenue.
In 1991, Seaberg co-founded ACIST Medical and served as its first President and CEO. ACIST manufactures and distributes power injection technologies for coronary angiography and was acquired by Bracco Ltd for $105 million in 2001. Earlier, he was also the founder and CEO of Seaberg Medical, a regional distributor of implantable cardiovascular devices.
Seaberg lives in Minneapolis. He holds a Bachelor of Arts in Speech Communications from the University of Minnesota and a Masters in Business Administration (MBA) from the Carlson School of Management, also at the University of Minnesota.

Mathew Ratty

Non Executive Director

Mathew Ratty is the co-founder of MC Management Group Pty Ltd, a long-only venture capital firm operating in the debt and equity space both domestically and internationally. Mathew also holds the role of Head of Investment and is responsible for negotiating deal structures and asset pricing for companies in the healthcare, financials and technology equities space. Throughout his time with MC Management, Mathew has achieved standout high returns (alpha) against the S&P 500 and also successfully managed multiple seed investments leading to over 250% returns for the company. From 2009-2013, Mathew worked as an analyst at Gladstone Bridge Pty Ltd, a property development and equity company. Based on his successful role, Mathew joined Gladstone as a Director, overseeing the asset allocation of the company. Mathew holds a Bachelor of Commerce degree (Property and Finance) with first class honours in Finance from Curtin University of Technology.

Simon Buckingham

Non Executive Director

Simon has more than 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Based in Sydney, Simon is a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Simon served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US.